HALO
Halozyme Therapeutics Inc
NASDAQ: HALO · HEALTHCARE · BIOTECHNOLOGY
$63.06
-1.25% today
Updated 2026-04-29
Market cap
$7.47B
P/E ratio
24.63
P/S ratio
5.35x
EPS (TTM)
$2.56
Dividend yield
—
52W range
$48 – $82
Volume
1.6M
WallStSmart proprietary scores
70
out of 100
Grade: B
Buy
Investment rating
10.0
Growth
A+6.3
Quality
B9.5
Profitability
A+5.3
Valuation
C+4/9
Piotroski F-Score
Moderate
2.9
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$85.78
+36.03%
12-Month target
$62.25
-1.28%
Intrinsic (DCF)
—
Margin of safety
—
2 Strong Buy4 Buy2 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Profit margin 22.70% — above average
+ ROE 153.60% — strong efficiency
+ Free cash flow $217.60M — positive
+ Revenue growth 51.60% QoQ
Risks
No major risks identified
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $660.12M | $829.25M | $1.02B | $1.40B | $1.40B |
| Net income | $202.13M | $281.59M | $444.09M | $316.89M | $-141.59M |
| EPS | — | — | — | — | $2.56 |
| Free cash flow | $235.30M | $373.28M | $468.37M | $644.59M | $217.60M |
| Profit margin | 30.62% | 33.96% | 43.74% | 22.69% | 22.70% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-06 | TORLEY, HELEN | Sale | 10,000 | $12.07 |
| 2026-04-06 | TORLEY, HELEN | Buy | 10,000 | $12.07 |
| 2026-04-06 | TORLEY, HELEN | Sale | 5,900 | $63.14 |
Peer comparison
Smart narrative
Halozyme Therapeutics Inc trades at $63.06. representing a P/E of 24.63x trailing earnings. Our Smart Value Score of 70/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.91, it sits in the grey zone. TTM revenue stands at $1.40B. with profit margins at 22.70%.
Frequently asked questions
What is Halozyme Therapeutics Inc's stock price?
Halozyme Therapeutics Inc (HALO) trades at $63.06.
Is Halozyme Therapeutics Inc overvalued?
Smart Value Score 70/100 (Grade B, Buy).
What is the price target of Halozyme Therapeutics Inc (HALO)?
The analyst target price is $85.78, representing +36.0% upside from the current price of $63.06.
What is Halozyme Therapeutics Inc's revenue?
TTM revenue is $1.40B.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
2.91 — grey zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio5.35x
ROE153.60%
Beta1.03
50D MA$66.49
200D MA$68.41
Shares out0.12B
Float0.12B
Short ratio—
Avg volume1.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—